AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023
Feb 13, 2023
30849_dirs_2023-02-13_fb72ff68-eac9-4695-8075-354d2cd8e918.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-02-09
Reporting Person: Chien Jennifer (EVP, Head of North America)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-09 | Common Stock | M | 3438 | — | Acquired | 4748 | Direct |
| 2023-02-09 | Common Stock | S | 1192 | $27.66 | Disposed | 3556 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-09 | Restricted Stock Units | $ | M | 3438 | Disposed | Common Stock (3438) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.